Sweden's Integrum Q1 sales rise on higher S1 surgeries

Integrum AB

03/09/2026 06:25

Overview
Sweden medical implant maker's fiscal Q1 net sales rose 27% yr/yr on higher S1 surgeries
Company posted positive EBITDA, aided by SEK 6.2 mln US customs duty refund
Gross margin improved, and lower costs contributed to stronger operating results

Outlook
Company did not provide specific financial guidance for the current quarter or full year

Result Drivers
HIGHER S1 SURGERY VOLUMES - Co said 48 S1 surgeries were performed in Q1, up 17% yr/yr, driving revenue growth
COST BASE REDUCTION - Co said lower external and personnel expenses contributed to improved EBITDA and profitability
CUSTOMS DUTY REFUND - SEK 6.2 mln refund of previously paid US customs duties boosted gross margin and EBITDA

Company press release: ID:nMFN1dT3st

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
 
SEK 30.20 mln
 
Q1 Operating profit
 
SEK 1.30 mln
 

Reuters Recommended Reads
Aug 31 - China's HeartCare Medical H1 revenue surges on stroke segment growth
Aug 31 - China's Angelalign H1 revenue rises on higher clear aligner case volume
Sept 1 - AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)